Navigation Links
ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists
Date:11/20/2009

PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswire-USNewswire/ -- In response to a recent New York Times article that questions why currently available medications designed to treat and prevent some cancers are being ignored, ECRI Institute, an independent nonprofit organization, is offering a roadmap to the evidence on Finasteride for Prevention of Prostate Cancer for free download.

The November 13, 2009, New York Times article, "Drugs to Deter Some Cancers Are Not Taken," was the most e-mailed article of the day from the Times and stimulated hundreds of comments on the publication's Web site. There is no simple answer about whether or which patients should take finasteride.

Medical decision makers in hospitals, health systems, public and private payer organizations, as well as medical journalists who are trying to clarify issues for themselves and for the public may benefit from consulting research references that form the evidence base for finasteride, one of the drugs discussed in the article. As a service to these constituencies, ECRI Institute is providing free access to its Hotline summary of resources and references.

"The summary of published literature and the perspectives we offer are drawn from the abstracts of key evidence sources," says Jeffrey C. Lerner, Ph.D., president and CEO, ECRI Institute. "We believe they are an excellent starting point for healthcare professionals, journalists, and the public to decide which complete reports to consult in forming and conveying their perspectives. In other words, this is a guide to the evidence literature."

The Hotline Response, Finasteride for Prevention of Prostate Cancer, was assembled by ECRI Institute's Evidence-based Practice Center staff of research analysts. The report, a component of ECRI Institute's subscription-based membership program, Health Technology Assessment Information Service(TM), is being distributed at no charge as a public service. The document is referred to as a "Hotline" report because it is a rapid response examination of research abstracts as opposed to a full quantitative and qualitative assessment of that evidence.

ECRI Institute's Health Technology Assessment Information Service provides new technology forecast profiles, Health Technology Trends newsletter articles, health technology assessments, and comparative-effectiveness reviews that evaluate technologies along the continuum from innovation to wide diffusion into practice. They are researched and written by a multidisciplinary staff of full-time doctoral-level research scientists, clinicians, medical technologists, medical librarians, and other healthcare professionals, which include ECRI Institute's Evidence-based Practice Center staff.

ECRI Institute has a rich history of providing assessments to hospitals, health systems, the U.S. Centers for Medicare & Medicaid Services and other federal agencies, as well as ministries of health and hospitals worldwide. To maintain objectivity in its research and publications, ECRI Institute requires all its employees to adhere to strong conflict-of-interest policies that keep employees at financial arm's length from medical product/pharmaceutical/biotechnology manufacturers and health plans.

For more information about ECRI Institute's Health Technology Assessment Information Service, visit www.ecri.org/htais, call (610) 825-6000, ext. 5060, e-mail htais@ecri.org, or write to 5200 Butler Pike, Plymouth Meeting, PA 19462.

About ECRI Institute

ECRI Institute (www.ecri.org), a nonprofit organization, dedicates itself to bringing the discipline of applied scientific research to healthcare to discover which medical procedures, devices, drugs, and processes are best to enable improved patient care. As pioneers in this science for 40 years, ECRI Institute marries experience and independence with the objectivity of evidence-based research. Strict conflict-of-interest guidelines ensure objectivity. ECRI Institute is designated a Collaborating Center of the World Health Organization and an Evidence-based Practice by the U.S. Agency for Healthcare Research and Quality. ECRI Institute PSO, listed as a federally certified Patient Safety Organization by the U.S. Department of Health and Human Services, strives to achieve the highest levels of safety and quality in healthcare by collecting and analyzing patient safety information and sharing lessons learned and best practices.


For more information, contact:
Laurie Menyo
(610) 825-6000, ext.  5310
lmenyo@ecri.org

SOURCE ECRI Institute


'/>"/>
SOURCE ECRI Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Karmanos Cancer Institute Launches Company and Innovative Breast Imaging Tool
2. Royal Institute of Technology Adopts OriGene Over-Expression Lysates in Human Proteome Atlas Program
3. Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes
4. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center First in the United States to Utilize Newly FDA-Cleared CARTO(R) 3 Navigation System
5. Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds
6. Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes
7. Solos Endoscopy, Inc. Receives Additional Purchase Orders from National Cancer Institute and National Institute of Health for its MammoView(TM) Product Line
8. ECRI Institute Sees Upward Trend in Hospital Medical Technology Evaluation Activity
9. National Institutes of Health Awards More Than $54 Million to Kaiser Permanente to Conduct Health Research
10. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
11. SRI International Awarded National Institute of Mental Health Contract for Evaluation of Brain Imaging Agents and Medications for Treatment of Mental Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... -- Niederländische Chirurgen haben eine innovative ... erlaubt, ihre Expertise weltweit zu teilen und so ... mit einer Instant-Messaging-Funktion und der Möglichkeit, in einem ... Afrika, Asien und den USA ... Information und Weiterbildung   "MDLinking ...
(Date:5/24/2016)... 2016 ARANZ Medical  Ltd a ... sector, has been named the Coretex Hi-Tech Emerging Company of ... Dr Bruce Davey , CEO of ARANZ Medical ... really good to be recognised for the work we are ... used in 35 countries around the world from Sub-Saharan Africa ...
(Date:5/24/2016)... , May 24, 2016 ... de doble terapia del mundo, introduce catéteres para ... OrbusNeich, una compañía global especializada en ... vidas, ha expandido su cartera incluyendo productos para ... JADE™ y Scoreflex™ PTA son los dispositivos de ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... W.S. Badger Co. Inc ... honored with a 2016 When Work Works Award for its use of effective workplace ... national When Work Works project administered by the Families and Work Institute (FWI) and ...
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, ... who lost their lives in military battle for the country. The nonprofit Hope ... to provide more programs that empower independence for disabled military veterans, as well as ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership ... solutions, today announced the organization has earned its ISO 13485 certification, indicating the ... compliant with all rules and policies associated with ISO quality standard 13485. ...
(Date:5/26/2016)... New York, NY (PRWEB) , ... May 26, ... ... cell researcher, founder of Mehling Orthopedics and chief medical officer of Blue Horizon ... Musculoskeletal Disease and Regeneration. The conference was held during May 5-6, 2016 in ...
Breaking Medicine News(10 mins):